Antibodies in metabolic diseases

New Biotechnology

Volumn 28, Issue 5, 2011, Pages 530-537

  Ahrens, Bianca ^a  

^a MORPHOSYS AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

FATTY LIVER; G PROTEIN COUPLED RECEPTORS; HIGH SPECIFICITY; INFLAMMATORY DISEASE; METABOLIC DISEASE; NEURODEGENERATIVE DISORDERS; OVER CURRENT; PATIENT COMPLIANCE; TECHNICAL FEASIBILITY; THERAPEUTIC ANTIBODIES; TREATMENT COSTS; TYPE II;

BIOCHEMISTRY; HEALTH RISKS; METABOLISM; NEURODEGENERATIVE DISEASES; NUTRITION; PATIENT TREATMENT; REGULATORY COMPLIANCE;

ANTIBODIES;

ANTIBODY; G PROTEIN COUPLED RECEPTOR 119; G PROTEIN COUPLED RECEPTOR 40; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCAGON RECEPTOR; INTERLEUKIN 1 ANTIBODY; INTERLEUKIN 1 RECEPTOR; RECEPTOR; SODIUM GLUCOSE COTRANSPORTER 2; UNCLASSIFIED DRUG;

ASTHMA; BIOAVAILABILITY; BRAIN; DIABETES MELLITUS; FATTY LIVER; GALLBLADDER DISEASE; HUMAN; INFLAMMATORY DISEASE; INSULIN DEPENDENT DIABETES MELLITUS; METABOLIC DISORDER; NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATHOGENESIS; PATIENT COMPLIANCE; PLASMA HALF LIFE; PRIORITY JOURNAL; REIMBURSEMENT; REVIEW;

ANIMALS; ANTIBODIES; CHRONIC DISEASE; DIABETES MELLITUS, TYPE 2; HUMANS; IMMUNOLOGIC TECHNIQUES;

EID: 80052808711     PISSN: 18716784     EISSN: 18764347     Source Type: Journal    
DOI: 10.1016/j.nbt.2011.03.022     Document Type: Review

References (78)

1. Hossain P., et al. Obesity and diabetes in the developing world-a growing challenge. N. Engl. J. Med. 2007, 356:213-215.
2. Ogden C.L., et al. The 2000 Centers for Disease Control and Prevention growth charts: several insights after 8 years. Nestle Nutr. Workshop Ser. Pediatr. Program 2010, 65:181-193.
3. Bethene Ervin R National Health Statistic Report (2009) 13:1-8.
4. Mathis D., et al. Beta-Cell death during progression to diabetes. Nature 2001, 414:792-798.
5. Saltiel A.R., Kahn C.R. Insulin signalling and the regulation of glucose and lipid metabolism. Nature 2001, 414:799-806.
6. Prentki M., Nolan C.J. Islet beta cell failure in type 2 diabetes. J. Clin. Invest. 2006, 116:1802-1812.
7. Mavian A.A., et al. Managing type 2 diabetes: balancing HbA1c and body weight. Postgrad. Med. 2010, 122:106-117.
8. Camastra S., et al. Effect of obesity and insulin resistance on resting and glucose-induced thermogenesis in man. EGIR (European Group for the Study of Insulin Resistance). Int. J. Obes. Relat. Metab. Disord. 1999, 23:1307-1313.
9. Bailey C.J. Drugs on the horizon for diabesity. Curr. Diab. Rep. 2005, 5:353-359.
10. Campbell R.K., White J.R. More choices than ever before: emerging therapies for type 2 diabetes. Diabetes Educ. 2008, 34:518-534.
11. Fonseca V. Clinical significance of targeting postprandial and fasting hyperglycemia in managing type 2 diabetes mellitus. Curr. Med. Res. Opin. 2003, 19:635-641.
12. Inzucchi S.E. Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA 2002, 287:360-372.
13. Owens D.R., et al. Insulins today and beyond. Lancet 2001, 358:739-746.
14. Dennis R.J., et al. Inadequate glucose control in type 2 diabetes is associated with impaired lung function and systemic inflammation: a cross-sectional study. BMC Pulm Med. 2010, 10:38.
15. Cnop M., et al. Mechanisms of pancreatic beta-cell death in type 1 and type 2 diabetes: many differences, few similarities. Diabetes 2005, 54(Suppl. 2):S97-107.
16. Donath M.Y., et al. Inflammatory mediators and islet beta-cell failure: a link between type 1 and type 2 diabetes. J. Mol. Med. 2003, 81:455-470.
17. Braddock M., Quinn A. Targeting IL-1 in inflammatory disease: new opportunities for therapeutic intervention. Nat. Rev. Drug Discov. 2004, 3:330-339.
18. Venieratos P.D., et al. High glucose induces suppression of insulin signalling and apoptosis via upregulation of endogenous IL-1beta and suppressor of cytokine signalling-1 in mouse pancreatic beta cells. Cell. Signal. 2010, 22:791-800.
19. Dinarello C.A., et al. Role of IL-1beta in type 2 diabetes. Curr. Opin. Endocrinol. Diabetes Obes. 2010, 17:314-321.
20. * http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001109/WC500031680.pdf.
21. Roell M.K., et al. Kinetic approach to pathway attenuation using XOMA 052, a regulatory therapeutic antibody that modulates interleukin-1beta activity. J. Biol. Chem. 2010, 285:20607-20614.
22. Lefebvre P.J. Glucagon and its family revisited. Diabetes Care 1995, 18:715-730.
23. Myers S.R., et al. Effects of small changes in glucagon on glucose production during a euglycemic, hyperinsulinemic clamp. Metabolism 1991, 40:66-71.
24. Baron A.D., et al. Role of hyperglucagonemia in maintenance of increased rates of hepatic glucose output in type II diabetics. Diabetes 1987, 36:274-283.
25. Lewis G.F., et al. Role of free fatty acids and glucagon in the peripheral effect of insulin on glucose production in humans. Am. J. Physiol. 1998, 275:E177-E186.
26. Shah P., et al. Lack of suppression of glucagon contributes to postprandial hyperglycemia in subjects with type 2 diabetes mellitus. J. Clin. Endocrinol. Metab. 2000, 85:4053-4059.
27. Brand C.L., et al. Immunoneutralization of endogenous glucagon with monoclonal glucagon antibody normalizes hyperglycaemia in moderately streptozotocin-diabetic rats. Diabetologia 1994, 37:985-993.
28. Liang Y., et al. Reduction in glucagon receptor expression by an antisense oligonucleotide ameliorates diabetic syndrome in db/db mice. Diabetes 2004, 53:410-417.
29. Sloop K.W., et al. Hepatic and glucagon-like peptide-1-mediated reversal of diabetes by glucagon receptor antisense oligonucleotide inhibitors. J. Clin. Invest. 2004, 113:1571-1581.
30. Staehr P., et al. Assessment of hepatic insulin action in obese type 2 diabetic patients. Diabetes 2001, 50:1363-1370.
31. Boden G., et al. Role of glucagon in disposal of an amino acid load. Am. J. Physiol. 1990, 259:E225-E232.
32. Pilkis S.J., Granner D.K. Molecular physiology of the regulation of hepatic gluconeogenesis and glycolysis. Annu. Rev. Physiol. 1992, 54:885-909.
33. Jiang G., Zhang B.B. Glucagon and regulation of glucose metabolism. Am. J. Physiol. Endocrinol. Metab. 2003, 284:E671-E678.
34. Brand C.L., et al. Role of glucagon in maintenance of euglycemia in fed and fasted rats. Am. J. Physiol. 1995, 269:E469-E477.
35. Brand C.L., et al. Evidence for a major role for glucagon in regulation of plasma glucose in conscious, nondiabetic, and alloxan-induced diabetic rabbits. Diabetes 1996, 45:1076-1083.
36. Sorensen H., et al. Immunoneutralization of endogenous glucagon reduces hepatic glucose output and improves long-term glycemic control in diabetic ob/ob mice. Diabetes 2006, 55:2843-2848.
37. Yan H., et al. Fully human monoclonal antibodies antagonizing the glucagon receptor improve glucose homeostasis in mice and monkeys. J. Pharmacol. Exp. Ther. 2009, 329:102-111.
38. Parker J.C., et al. Glycemic control in mice with targeted disruption of the glucagon receptor gene. Biochem. Biophys. Res. Commun. 2002, 290:839-843.
39. Gutniak M., et al. Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus. N. Engl. J. Med. 1992, 326:1316-1322.
40. Drucker D.J. The biology of incretin hormones. Cell Metab. 2006, 3:153-165.
41. Holst J.J., Deacon C.F. Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes. Diabetes 1998, 47:1663-1670.
42. Ahren B. Islet G protein-coupled receptors as potential targets for treatment of type 2 diabetes (reprinted from Nat. Rev. Drug Discov. 2009;8:369-385). Nat. Rev. Drug Discov. 2010, 12-28.
43. DeFronzo R.A., et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005, 28:1092-1100.
44. Kendall D.M., et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005, 28:1083-1091.
45. Barber T.M., et al. The incretin pathway as a new therapeutic target for obesity. Maturitas 2010, 67:197-202.
46. Ahren B. Emerging dipeptidyl peptidase-4 inhibitors for the treatment of diabetes. Expert Opin. Emerg. Drugs 2008, 13:593-607.
47. Kieffer T.J. GIP or not GIP? That is the question. Trends Pharmacol. Sci. 2003, 24:110-112.
48. Dupre J., et al. Stimulation of insulin secretion by gastric inhibitory polypeptide in man. J. Clin. Endocrinol. Metab. 1973, 37:826-828.
49. Trumper A., et al. Glucose-dependent insulinotropic polypeptide is a growth factor for beta (INS-1) cells by pleiotropic signaling. Mol. Endocrinol. 2001, 15:1559-1570.
50. Meier J.J., et al. Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia. Diabetologia 2003, 46:798-801.
51. Vilsboll T., et al. Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients. Diabetologia 2002, 45:1111-1119.
52. Piteau S., et al. Reversal of islet GIP receptor down-regulation and resistance to GIP by reducing hyperglycemia in the Zucker rat. Biochem. Biophys. Res. Commun. 2007, 362:1007-1012.
53. Miyawaki K., et al. Inhibition of gastric inhibitory polypeptide signaling prevents obesity. Nat. Med. 2002, 8:738-742.
54. Gault V.A., et al. Chemical gastric inhibitory polypeptide receptor antagonism protects against obesity, insulin resistance, glucose intolerance and associated disturbances in mice fed high-fat and cafeteria diets. Diabetologia 2007, 50:1752-1762.
55. Irwin N., et al. Early administration of the glucose-dependent insulinotropic polypeptide receptor antagonist (Pro3)GIP prevents the development of diabetes and related metabolic abnormalities associated with genetically inherited obesity in ob/ob mice. Diabetologia 2007, 50:1532-1540.
56. McClean P.L., et al. GIP receptor antagonism reverses obesity, insulin resistance, and associated metabolic disturbances induced in mice by prolonged consumption of high-fat diet. Am. J. Physiol. Endocrinol. Metab. 2007, 293:E1746-E1755.
57. Fulurija A., et al. Vaccination against GIP for the treatment of obesity. PLoS One 2008, 3:e3163.
58. Irwin N., et al. Active immunisation against gastric inhibitory polypeptide (GIP) improves blood glucose control in an animal model of obesity-diabetes. Biol. Chem. 2009, 390:75-80.
59. Bartoov-Shifman R., et al. Regulation of the gene encoding GPR40, a fatty acid receptor expressed selectively in pancreatic beta cells. J. Biol. Chem. 2007, 282:23561-23571.
60. Brownlie R., et al. The long-chain fatty acid receptor, GPR40, and glucolipotoxicity: investigations using GPR40-knockout mice. Biochem. Soc. Trans. 2008, 36:950-954.
61. Flodgren E., et al. GPR40 is expressed in glucagon producing cells and affects glucagon secretion. Biochem. Biophys. Res. Commun. 2007, 354:240-245.
62. Itoh Y., et al. Free fatty acids regulate insulin secretion from pancreatic beta cells through GPR40. Nature 2003, 422:173-176.
63. Salehi A., et al. Free fatty acid receptor 1 (FFA(1)R/GPR40) and its involvement in fatty-acid-stimulated insulin secretion. Cell Tissue Res. 2005, 322:207-215.
64. Edfalk S., et al. Gpr40 is expressed in enteroendocrine cells and mediates free fatty acid stimulation of incretin secretion. Diabetes 2008, 57:2280-2287.
65. Latour M.G., et al. GPR40 is necessary but not sufficient for fatty acid stimulation of insulin secretion in vivo. Diabetes 2007, 56:1087-1094.
66. Steneberg P., et al. The FFA receptor GPR40 links hyperinsulinemia, hepatic steatosis, and impaired glucose homeostasis in mouse. Cell Metab. 2005, 1:245-258.
67. Vettor R., et al. Loss-of-function mutation of the GPR40 gene associates with abnormal stimulated insulin secretion by acting on intracellular calcium mobilization. J. Clin. Endocrinol. Metab. 2008, 93:3541-3550.
68. Bharate S.B., et al. Discovery of diacylphloroglucinols as a new class of GPR40 (FFAR1) agonists. Bioorg. Med. Chem. Lett. 2008, 18:6357-6361.
69. Hirasawa A., et al. Free fatty acid receptors and drug discovery. Biol. Pharm. Bull. 2008, 31:1847-1851.
70. Overton H.A., et al. GPR119, a novel G protein-coupled receptor target for the treatment of type 2 diabetes and obesity. Br. J. Pharmacol. 2008, 153:S76-S81.
71. Chu Z.L., et al. A role for beta-cell-expressed G protein-coupled receptor 119 in glycemic control by enhancing glucose-dependent insulin release. Endocrinology 2007, 148:2601-2609.
72. Soga T., et al. Lysophosphatidyleholine enhances glucose-dependent insulin secretion via an orphan G-protein-coupled receptor (vol 326, pg 744, 2005). Biochem. Biophys. Res. Commun. 2005, 329:417.
73. Sakamoto Y., et al. Expression and distribution of Gpr119 in the pancreatic islets of mice and rats: predominant localization in pancreatic polypeptide-secreting PP-cells. Biochem. Biophys. Res. Commun. 2006, 351:474-480.
74. Jones R.M., et al. GPR119 agonists for the treatment of type 2 diabetes. Expert Opin. Ther. Patients 2009, 19:1339-1359.
75. Semple G., et al. Discovery of the first potent and orally efficacious agonist of the orphan G-protein coupled receptor 119. J. Med. Chem. 2008, 51:5172-5175.
76. Wu Y., et al. 2,5-Disubstituted pyridines as potent GPR119 agonists. Bioorg. Med. Chem. Lett. 2010, 20:2577-2581.
77. Chao E.C., Henry R.R. SGLT2 inhibition-a novel strategy for diabetes treatment. Nat. Rev. Drug Discov. 2010, 9:551-559.
78. Farber S.J., et al. Effect of diabetes and insulin of the maximum capacity of the renal tubules to reabsorb glucose. J. Clin. Invest. 1951, 30:125-129.